Drugs Made in America Acquisition CORP

Drugs Made In America Acquisition Corp. (DMAA) has amended its merger agreement with Power Analytics Global Corp (PAGC), introducing changes to sponsor shares, rights treatment, and financing, while also outlining a contingent amendment for a potential three-party combination.

Drugs Made In America Acquisition Corp. (DMAA) has entered into a definitive merger agreement to acquire Power Analytics Global Corp (PAGC) at a $1 billion target enterprise valuation.

Shareholders approved a 12-month extension to complete a business combination, with 9.44 million shares redeemed.

Drugs Made In America Acquisition Corp. has formalized compensation agreements for its CFO and CEO, including monthly fees and share grants tied to a future business combination.

Drugs Made In America Acquisition Corp. has entered into a non-binding letter of intent to combine with Power Analytics Global Corp., valuing the target at approximately $1 billion.

Drugs Made In America Acquisition Corp. secured an initial $100,000 interim convertible note from BV Advisory Partners, LLC, as part of a larger $500,000 financing commitment to pursue a new business combination in enterprise technology.

Drugs Made in America Acquisition Corp. reports Q1 2026 net income of $1.97 million, driven by trust account interest, while continuing its search for a business combination.

Drugs Made In America Acquisition Corp. reports net income of $5.7 million for the nine months ended September 30, 2025, driven by trust account interest, but faces going concern doubts.

Drugs Made In America Acquisition Corp., a blank check company, reported net income driven by trust account interest but faces a going concern warning and internal control weaknesses.

Drugs Made In America Acquisition Corp. reports a net income of $1,254,543 for the quarter ended March 31, 2025, primarily due to interest earned on its trust account.

Drugs Made In America Acquisition Corp. reports management turnover, material internal control weaknesses, and a potential $1 billion de-SPAC target.

Drugs Made In America Acquisition Corp. files its annual report on Form 10-K, detailing its focus on acquiring a pharmaceutical business in the U.S. and its financial activities since its IPO.

Drugs Made In America Acquisition Corp. has amended its merger agreement with Power Analytics Global Corp, introducing changes to sponsor share treatment, rights offers, and potential for a three-party combination.

Drugs Made In America Acquisition Corp. has entered into a definitive merger agreement to acquire Power Analytics Global Corp. at a target enterprise valuation of $1 billion.

Drugs Made In America Acquisition LLC, a 10% owner and director, acquired 30,000 private units of Drugs Made In America Acquisition Corp. at $10 per unit on February 18, 2025.

Lynn Stockwell, Director, CEO, and Executive Chair of Drugs Made In America Acquisition Corp., reports acquiring 30,000 private units for $300,000, increasing her indirect holdings.

Drugs Made In America Acquisition LLC, a 10% owner of Drugs Made In America Acquisition Corp., reports transactions involving ordinary shares and rights to receive ordinary shares.

Lynn Stockwell, a director, 10% owner, CEO, and Executive COB of Drugs Made In America Acquisition Corp., reported the transfer and disposal of ordinary shares and rights to receive ordinary shares on January 29, 2025.

Drugs Made in America Acquisition Corp. is holding an extraordinary general meeting on April 27, 2026, to seek shareholder approval for an extension of its deadline to complete a business combination, proposing to move the termination date from April 29, 2026, to April 29, 2027.

Drugs Made In America Acquisition Corp. files an amendment to its S-1 registration statement, primarily consisting of exhibits and updated signatures.

Drugs Made In America Acquisition Corp., a blank check company, filed an amendment to its S-1 registration statement for a proposed $200 million initial public offering.

Drugs Made In America Acquisition Corp., a blank check company focused on the pharmaceutical industry, has filed Amendment No. 4 to its registration statement for a proposed $200 million initial public offering.

Drugs Made In America Acquisition Corp., a blank check company targeting the pharmaceutical industry, has filed Amendment No. 3 to its Form S-1 registration statement for a $200 million initial public offering.

Drugs Made In America Acquisition Corp. has filed an amendment to its registration statement for a $500 million initial public offering targeting the pharmaceutical industry.

Drugs Made In America Acquisition Corp., a blank check company targeting the pharmaceutical industry, has filed an amendment to its S-1 registration statement for a proposed $500 million initial public offering.

Drugs Made In America Acquisition LLC and its managing member, Lynn Stockwell, have filed a Schedule 13D disclosing a 12.5% beneficial ownership stake in Drugs Made In America Acquisition Corp., totaling 4,188,780 ordinary shares.

Feis Equities LLC and Lawrence M. Feis have filed a Schedule 13G reporting a 5.08% beneficial ownership stake in Drugs Made In America Acquisition Corp.

Mizuho Financial Group, Inc. has filed a Schedule 13G, reporting beneficial ownership of 6.0% of Drugs Made In America Acquisition Corp. common shares.

Hudson Bay Capital Management LP and Sander Gerber report a 4.62% beneficial ownership stake in Drugs Made In America Acquisition Corp. ordinary shares.

Karpus Management, Inc. has disclosed an 8.19% beneficial ownership stake in Drugs Made In America Acquisition Corp., holding over 2.7 million common shares.

Multiple First Trust entities, including First Trust Merger Arbitrage Fund and First Trust Capital Management L.P., have disclosed passive beneficial ownership exceeding 5% in Drugs Made In America Acquisition Corp.'s Class A Ordinary Shares.

Glazer Capital, LLC and its managing member, Paul J. Glazer, have disclosed a beneficial ownership of 5.44% in Drugs Made in America Acquisition Corp.'s Ordinary Shares.